EU panel backs approval of pomalidomide for multiple myeloma

Celgene International's oral pomalidomide has been recommended for approval against multiple myeloma by the European Medicines Agency's Committee for Medicinal Products for Human Use. The panel concluded that the drug's benefits are greater than its risks in people who have been given at least two previous treatments including both lenalidomide and bortezomib. The drug was approved in the U.S. this year with the brand name Pomalyst.

View Full Article in:

Medscape (free registration) · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC